{
    "nct_id": "NCT05053555",
    "official_title": "High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies",
    "inclusion_criteria": "* GROUP A: Patients with liver lesions must be over the age of 18\n* GROUP A: Any patient with up to five unresectable tumors that are:\n\n  * At least 3 cm (largest diameter in the axial plane)\n  * In close proximity to large blood vessels\n  * In close proximity to sensitive structures (bowel, stomach, diaphragm, liver capsule, liver hilum, bile ducts)\n  * Associated with difficult endovascular access to one or more feeding arterial branches (hypovascular tumors)\n  * Associated with a large shunt fraction to other vital organs\n* GROUP B: Historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021\n\nExclusion criteria:\n\n* Active infectious disease\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients with polymetastatic disease with the exception of those patients who may benefit from therapy addressing local complications directly related to the target lesion diminishing quality of life such as pain, vascular/biliary occlusion, and liver disfunction\n* Pregnancy (sexually active patients must be on birth control while participating in this study)\n* Child-Pugh class C\n* Total serum bilirubin > 2 mg/dl\n* Platelet count < 50,000/ul\n* International normalized ratio (INR) > 1.5\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}